**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Diane Xavier de Avila,  Fluminense Federal University, Postgraduate Program in Cardiovascular Sciences, Niterói, Rio de Janeiro State, Brazil. and Complexo Hospitalar de Niterói, DASA Brazil.

**Main Body of the Abstract**
Background: Multiple myeloma primarily affects the bone marrow (BM), resulting in bone lesions and BM failure. In contrast, amyloidosis primarily impacts organs and tissues due to the deposition of amyloid proteins. The gradual proliferation of plasma cell clones in the BM leads to the secretion of unstable immunoglobulin-free light chains (FLC), which infiltrate peripheral tissues, causing significant organ damage. The clinical presentation of amyloidosis is often nonspecific. Here, we present an atypical case involving heart failure with preserved ejection fraction, along with an association of MM and amyloidosis, suspected by low voltage at eletrocardiogram and “hypertrophy” (figure1A),
Clinical Case: A 62-year-old woman with a history of recent breast cancer treatment presented with chronic musculoskeletal pain, bilateral carpal tunnel syndrome, biceps tenosynovitis, changes in bowel habits, periorbital ecchymosis, dyspnea, anasarca, and worsening renal function. Investigation revealed multiple myeloma confirmed by BM biopsy (plasmocytoma). Recurrent pleural effusion (1B) necessitated local biopsy, confirming amyloidosis with positive Congo red staining (1C). Liquid chromatography coupled to ultra-resolution tandem mass spectrometry detected a peptide profile consistent with LAMBDA-type immunoglobulin light chain, the amyloid deposit protein. Abdominal fat biopsy also confirmed free light chains (1D). The patient is undergoing treatment with daratumumab-CyBorD.
Conclusion: AL amyloidosis is a systemic disease, and diagnosing amyloid protein deposition guides appropriate treatment, improving prognosis. Each biopsy opportunity providing documented amyloid protein is invaluable for tailored management.



Recurrent pleural effusion and AL amyloidosis diagnosis PA85 (#534)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.